Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis

Modern Rheumatology

Volumn 10, Issue 3, 2000, Pages 160-164

  Nakamura, T ^a   Baba, S ^b   Yamamura, Y ^a   Tsuruta, T ^a   Matsubara, S ^a   Tomoda, K ^a   Tsukano, M ^a  

^a Kumamoto Center for Arthritis and Rheumatology   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunosuppressive therapy; Rheumatoid arthritis; SAA1 amyloidosis

Indexed keywords

EID: 84981220132     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/s101650070024     Document Type: Article

References (15)

1. Kobayashi H, Tada S, Fuchigami T, Okuda Y, Takasugi K, Matsumoto T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastro-duodenal biopsy. Br J Ftheumatol 1996; 35: 44 – 9.
2. Suzuki A, Ohosone Y, Obana M, Mita S, Matsuoka Y, Irimajiri S, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Ftheumatol 1994; 21: 33 – 6.
3. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatic disease. Ann Rheum Dis 1987; 46: 763 – 7.
4. Falck HM, Tornroth T, Skrifvars B, Wegelius O. Resolution of renal amyloidosis secondary to rheumatoid arthritis. Acta Med Scand 1979; 205: 651 – 6.
5. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38: 1851 – 4.
6. Hanzenberg BC, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Bailhere's Clin Ftheumatol 1994; 8: 661 – 90.
7. Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allele variant of serum amyloid A, SAA1y: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995; 4: 1083 – 7.
8. Gertz MA, Kyle RA, Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991; 77: 257 – 62.
9. Fiter J, Nolla J-M, Valverde J, Roig-Escofet D. Treatment of amyloidosis secondary to rheumatoid arthritis. J Ftheumatol 1995; 22: 569 – 70.
10. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10-21-year follow-up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Ftheumatol 1993; 20: 2051 – 7.
11. Migita K, Eguchi K, Tsukada T, Kawabe Y, Takashima H, Mine M, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75: 371 – 5.
12. Hasegawa H, Nishi S, Ito S, Saeki T, Kuroda T, Kimura H, et al. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis Rheum 1996; 39: 1728 – 32.
13. Teppo AM, Maury CPJ. Urinary protein excretion patterns in reactive (secondary) systemic amyloidosis. Rheumatol Int 1988; 8: 213 – 7.
14. Murakami H, Ura N, Nagao K, Tsuchihashi K, Nakata T, Agata T, et al. Rheumatoid arthritis associated with renal amyloidosis and crescentic glomerulonephritis. Intern Med 1998; 37: 94 – 7.
15. Baba S, Miyamoto S, Kawashima M, Nakai H, Goto M, Morris BJ, et al. Serum amyloid A gene polymorphonism and AA-amyloi-dosis. In: Kyle RA, Gertz MA, editors. Amyloid and amyloidosis. New York: Pathenon; 1998. p. 417 – 9.